SRSneha Rochlani

Sneha Rochlani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sneha Rochlani has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • LTTM mediated environmentally benign synthesis of novel thiazole derivatives: Computational & biological investigations

    by Prasad Swami, Dnyaneshwar Kshirsagar, Sneha Rochlani, Nagesh Birajdar, Lalit Bhosale, Sandip Deshmukh, Sandeep Sankpal, Shankar Hangirgekar

  • [DMAP-DABCO]AcO as a basic ionic liquid for ultrasound assisted domino synthesis of N-amino-2-pyridone derivatives and their molecular docking study

    by Pravin Kharade, Dipak Gaikwad, Santosh Chobe, Uttam Chougale, Satish Kadam, Sneha Rochlani, Savita Desai


  • Exploring quinazolinone linked 1,4-disustituted mono- and bis-1,2,3-triazole derivatives: A combined synthetic, anticancer, and molecular docking study

    by Shyam V. Londhe, Shubham M. Sulakhe, Shriram B. Pawar, Abhishek K. Khanzode, Somesh S. Salunke, Sneha Rochlani, Prafulla B. Choudhari, Kishan P. Haval


  • Novel Flavonols from Macaranga Inermis as Promising M pro Inhibitors: A Quantum Mechanical and In Silico Investigation for Pan‐Coronavirus Targeting

    by Sneha Rochlani, Manish Bhatia

    Flavonoids, a vital class of phytochemicals, are known for their diverse pharmacological activities, including potent antiviral effects. This study evaluates two newly reported flavonols, macainermisin A and macainermisin B, as potential inhibitors of the main protease (M pro ) across multiple coronavirus variants using an integrated in silico approach comprising DFT calculations, molecular docking, ADMET/drug‐likeness profiling, and 100 ns molecular dynamics simulations. Docking studies revealed that macainermisin A exhibited binding affinities ranging from −7.5 to −8.6 kcal/mol, while macainermisin B showed even stronger binding, with a highest affinity of −8.5 kcal/mol against M pro from SARS‐CoV‐2 (PDB ID: 8HVK). DFT analysis confirmed structural stability across gas and solvent phases, with negligible geometric distortions. However, chemical reactivity descriptors (e.g., HOMO–LUMO gap, electrophilicity index) varied significantly with solvent polarity, indicating favorable energetic adaptation. ADMET profiling showed high gastrointestinal absorption (>90%), non‐hepatotoxicity, no CYP2D6 inhibition, and an acceptable logP value of macainermisin B, supporting good oral bioavailability. Drug‐likeness filters (Lipinski, Veber, and Ghose rules) were satisfied for both compounds. Molecular dynamics simulations confirmed the stability of the M pro –macainermisin A complex (8HOL) over 100 ns, with low RMSD (pro , warranting further experimental validation.

  • One-pot synthesis of novel hydrazinyl thiazoles using rust and Ficus benghalensis leaf derived Fe2O3/ZrO2 nano-catalyst: Their molecular docking, ADME, antidiabetic, and antioxidant study

    by Akshay Gurav, Lalit Bhosale, Prakash N. Chavan, Rutikesh Gurav, Nisha Nerlekar, Padma Dandge, Sneha Rochlani, Sandeep Sankpal, Shankar Hangirgekar


  • High-throughput computational screening for identification of potential hits against bacterial Acriflavine resistance protein B (AcrB) efflux pump

    by Sanket Rathod, Sreenath Dey, Prafulla Choudhari, Deepak Mahuli, Sneha Rochlani, Rakesh Dhavale, Somdatta Chaudhari, Yasinalli Tamboli, Jaydeo Kilbile, Eerappa Rajakumara

    Antibiotic resistance is a pressing global health challenge, driven in part by the remarkable efflux capabilities of efflux pump in AcrB (Acriflavine Resistance Protein B) protein in Gram-negative bacteria. In this study, a multi-approached computational screening strategy encompassing molecular docking, In silico absorption, distribution, metabolism, excretion and toxicity (ADMET) analysis, druglikeness assessment, molecular dynamics simulations and density functional theory studies was employed to identify novel hits capable of acting against AcrB-mediated antibiotic resistance. Ligand library was acquired from the COCONUT database. Performed computational analyses unveiled four promising hit molecules (CNP0298667, CNP0399927, CNP0321542 and CNP0269513). Notably, CNP0298667 exhibited the highest negative binding affinity of -11.5 kcal/mol, indicating a possibility of strong potential to disrupt AcrB function. Importantly, all four hits met stringent druglikeness criteria and demonstrated favorable in silico ADMET profiles, underscoring their potential for further development. MD simulations over 100 ns revealed that the CNP0321542-4DX5 and CNP0269513-4DX5 complexes formed robust and stable interactions with the AcrB efflux pump. The identified hits represent a promising starting point for the design and optimization of novel therapeutics aimed at combating AcrB-mediated antibiotic resistance in Gram-negative bacteria.Communicated by Ramaswamy H. Sarma.


  • Exploration of limonoids for their broad spectrum antiviral potential via DFT, molecular docking and molecular dynamics simulation approach

    by Sneha Rochlani, Manish Bhatia, Sanket Rathod, Prafulla Choudhari, Rakesh Dhavale

    Limonoids serve as vital secondary metabolites. Citrus limonoids show a wide range of pharmacological potential. As a result of which limonoids from citrus are of considerable research interest. Identification of new therapeutic molecules from natural origins has been widely adopted as a successful strategy in drug discovery. This work mainly focused on the high-throughput computational exploration of the antiviral potential of three vital limonoids, i.e. Obacunone, Limonin and Nomilin against spike proteins of SARS CoV-2 (PDB:6LZG), Zika virus NS3 helicase (PDB:5JMT), Serotype 2 RNA dependent RNA polymerase of dengue virus (PDB:5K5M). Herein we report the molecular docking, MD simulation studies of nine docked complexes, and density functional theory (DFT) of selected limonoids. The results of this study indicated that all three limonoids have good molecular features but out of these three obacunone exerted satisfactory results for DFT, docking and MD simulation study. Graphical Abstract


  • Exploring biogenic chalcones as DprE1 inhibitors for antitubercular activity via in silico approach

    by Sanket Rathod, Pooja Chavan, Deepak Mahuli, Sneha Rochlani, Shalini Shinde, Swaranjali Pawar, Prafulla Choudhari, Rakesh Dhavale, Pralhad Mudalkar, Firoj Tamboli

    Cases of drug-resistant tuberculosis (TB) have increased worldwide in the last few years, and it is a major threat to global TB control strategies and the human population. Mycobacterium tuberculosis is a common causative agent responsible for increasing cases of TB and as reported by WHO, approximately, 1.5 million death occurred from TB in 2020. Identification of new therapies against drug-resistant TB is an urgent need to be considered primarily. The current investigation aims to find the potential biogenic chalcone against the potential targets of drug-resistant TB via in silico approach. The ligand library of biogenic chalcones was screened against DprE1. Results of molecular docking and in silico ADMET prediction revealed that ZINC000005158606 has lead-like properties against the targeted protein. Pharmacophore modeling was done to identify the pharmacophoric features and their geometric distance present in ZINC000005158606. The binding stability study performed using molecular dynamics (MD) simulation of the DprE1-ZINC000005158606 complex revealed the conformational stability of the complex system over 100 ns with minimum deviation. Further, the in silico anti-TB sensitivity of ZINC000005158606 was found to be higher as compared to the standards against Mycobacterium tuberculosis. The overall in silico investigation indicated the potential of identified hit to act as a lead molecule against Mycobacterium tuberculosis. Graphical Abstract


  • Phytochemical and Pharmacophoric Fragment Based Anticancer Drug Development

    by Sneha P. Rochlani, Lalita K. Dahiwade, Prafulla B. Choudhari

    Background: Cancer is the leading cause of death in the current decade. With the advancement in scientific technologies various treatments had been introduced but they suffer from numerous side effects. The root cause of cancer is alteration in the cell cycle which generates cancerous cells. Development of new lead which specifically target cancerous cells is needed to reduce the side effect and to overcome multidrug resistance. Objective: Design and development of anticancer leads targeting colchicine site of microtubules using structurally screened phytofragments is the primary objective of this work. Material and methods: Bioactive fragments of phytoconstituents were identified from a large dataset of phytochemicals. The identified phytofragments were used to design structures which were screened for virtual interactions with colchicine site of microtubules. Selected set of designed molecules was further screened for drug like properties and toxicity. The designed molecules which surpassed virtual filters were then synthesized, characterized and further screened for anticancer potential against HEPG2 liver cancer cellline. Result: A novel series of chalcones was designed by phytofragment based drug design. The synthesized compounds showed profound anticancer activity comparable to standard, 5-fluoro uracil. In the present communication, rational development of anticancer leads targeting colchicine site of microtubules has been done by integrating pocket modeling and virtual screening with synthesis and biological screening. Conclusion: In this present work, we found that compound S4 and S3 showed specific interaction with colchicine site of microtubules and desirable anticancer activity. Further optimization of the lead could yield drug like candidate with reduced side effects and may overcome multidrug resistance.


  • Multi-Targeted Design and Development of Dihydroisoquinolines as Potent Antimalarials

    by Raviraj V. Mule, Sneha P. Rochlani, Prafulla B. Choudhari, Rakesh P. Dhavale, Manish S. Bhatia

    Background: Malaria is a serious parasitic infection with greater morbidity and motility in recent decades. Cysteine protease and DHODH enzyme serve as a potential target for antimalarial agents which inhibit parasite multiplication in the erythrocyte stage. Development of new leads which specifically target cysteine protease and DHODH enzyme can reduce the side effects and overcome multidrug resistance. Objectives: Representing the design and development of antimalarial agents by targeting cysteine protease and DHODH (Dihydroorotate dehydrogenase) enzyme by structure-based drug design. Methods: In present work, the rational development of antimalarial agents by targeting cysteine protease and DHODH has been made by integrating binding confirmation from virtual analysis and synthetic procedures. Result: A novel series of dihydroisoquinolines was designed by structure-based drug design. Compounds from the dataset were screened for interaction at the target site by performing molecular docking study and subsequently, all molecules were screened for drug-like properties and toxicity, prior to synthesis molecules subjected to virtual filters. Designed molecules which exceed these virtual filters were synthesized, characterized and finally screened for antimalarial activity. Conclusion: In this work, it has been observed that compound A1, A5, A6 and A9 showed desirable biological activity towards targets and also specific hydrogen bonding interaction with the targets. Further optimization in leads yields a drug-like candidate and may overcome multidrug resistance.